NCT02431559 2022-10-10Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian CancerLudwig Institute for Cancer ResearchPhase 1/2 Completed53 enrolled 22 charts